Azedra
Neoplasm Metastasis, Heart failure, scintigraphy + 9 more
Treatment
0 Active Studies for Azedra
Treatment for
Neoplasm Metastasis
What is Azedra
Iobenguane
The Generic name of this drug
Treatment Summary
MIBG is a synthetic medication used to locate phaeochromocytomas and neuroblastomas, which are tumors that produce hormones. MIBG is combined with an imaging radioisotope, either iodine-123 or iodine-131, to create an image. The iodine-131 can also be used to destroy the tissues that metabolize noradrenaline. This drug was approved by the FDA in 2008.
Iobenguane Sulfate I 131 Injection
is the brand name
Azedra Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Iobenguane Sulfate I 131 Injection
Iobenguane
1994
3
Effectiveness
How Azedra Affects Patients
AdreView is a type of imaging drug used to help diagnose patients. It contains a very small amount of a chemical called iobenguane, which does not have any effects on the body. Patients with kidney problems may have an increased amount of radiation from this drug and have poorer imaging results.
How Azedra works in the body
Iobenguane looks similar to a chemical found naturally in the body called noradrenaline. This similarity allows it to be taken up by the body's organs, and stored in tiny sacs called vesicles. The radioactive iodine in iobenguane is what makes it useful as an imaging agent.
When to interrupt dosage
The proposed dosage of Azedra is contingent upon the diagnosed condition, including Neoplasm Metastasis, scintigraphy and Neoplasm Metastasis. The amount of dosage fluctuates, in accordance with the administration approach (e.g. Injection, solution - Intravenous or Intravenous) set out in the following table.
Condition
Dosage
Administration
Neoplasm Metastasis
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Heart failure
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
scintigraphy
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Pheochromocytoma
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Pheochromocytoma
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Myocardium
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Pheochromocytoma
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Paraganglioma
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Neuroblastoma
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Advance Directives
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
LVEF ≤35%
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Neoplasm Metastasis
, 15.0 mCi/mL, 2.0 mCi/mL, 2.3 mCi/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, Injection - Intravenous
Warnings
Azedra has one identified contraindication, and thus should not be administered when encountering any of the conditions outlined in the table below.
Azedra Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Iobenguane may interact with Pulse Frequency
Common Azedra Drug Interactions
Drug Name
Risk Level
Description
Azedra Toxicity & Overdose Risk
The lowest toxic dose of the drug for a mouse is 300 mg/kg, for a rabbit it is 3200 mg/kg, and for a rat it is 980 mg/kg. The most common side effects in patients are dizziness, rash, itching, flushing, headache, and bleeding at the injection site, occurring in less than 1.3% of patients.
Azedra Novel Uses: Which Conditions Have a Clinical Trial Featuring Azedra?
At present, no active trials are examining the potential of Azedra to provide relief from Neoplasm Metastasis, Neoplasm Metastasis and Pheochromocytoma.
Condition
Clinical Trials
Trial Phases
scintigraphy
0 Actively Recruiting
Pheochromocytoma
0 Actively Recruiting
Heart failure
0 Actively Recruiting
Myocardium
0 Actively Recruiting
Paraganglioma
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
LVEF ≤35%
0 Actively Recruiting
Pheochromocytoma
0 Actively Recruiting
Pheochromocytoma
0 Actively Recruiting
Neoplasm Metastasis
0 Actively Recruiting
Neuroblastoma
0 Actively Recruiting
Neoplasm Metastasis
0 Actively Recruiting
Patient Q&A Section about azedra
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Which of the following are symptoms of pheochromocytoma?
"The symptoms of a panic attack include high blood pressure, headache, heavy sweating, rapid heartbeat, tremors, pallor, and shortness of breath."
Answered by AI
What is azedra used for?
"Azedra is a medication used to treat adult and pediatric patients with pheochromocytoma and paraganglioma, who are 12 years or older, and who have cancer that is positive for the norepinephrine transporter (determined by an iobenguane scan). This medication requires systemic anticancer therapy."
Answered by AI
What is azedra?
"A drug that contains radioactive iodine and is used to treat adults and children aged 12 years and older with certain types of cancer that have spread or cannot be removed by surgery."
Answered by AI
Is azedra FDA approved?
"The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original site (metastatic), or have returned after surgery (recurrent)."
Answered by AI